Most herpes simplex virus 2 (HSV-2) reactivations in humans are subclinical and associated with rapid expansion and containment of virus. Previous studies have shown that CD8 1 T cells persist in genital skin and mucosa at the dermal-epidermal junction (DEJ)the portal of neuronal release of reactivating virus-for prolonged time periods after herpes lesions are cleared 1,2 . The phenotype and function of this persistent CD8 1 T-cell population remain unknown. Here, using cell-type-specific laser capture microdissection, transcriptional profiling and T-cell antigen receptor b-chain (TCRb) genotyping on sequential genital skin biopsies, we show that CD8aa 1 T cells are the dominant resident population of DEJ CD8 1 T cells that persist at the site of previous HSV-2 reactivation. CD8aa 1 T cells located at the DEJ lack chemokine-receptor expression required for lymphocyte egress and recirculation, express gene signatures of T-cell activation and antiviral activity, and produce cytolytic granules during clinical and virological quiescent time periods. Sequencing of the TCR b-chain repertoire reveals that the DEJ CD8aa 1 T cells are oligoclonal with diverse usage of TCR variable-b genes, which differ from those commonly described for mucosa-associated invariant T cells and natural killer T cells. Dominant clonotypes are shown to overlap among multiple recurrences over a period of two-and-a-half years. Episodes of rapid asymptomatic HSV-2 containment were also associated with a high CD8 effector-to-target ratio and focal enrichment of CD8aa 1 T cells. These studies indicate that DEJ CD8aa 1 T cells are tissue-resident cells that seem to have a fundamental role in immune surveillance and in initial containment of HSV-2 reactivation in human peripheral tissue. Elicitation of CD8aa 1 T cells may be a critical component for developing effective vaccines against skin and mucosal infections.
Most herpes simplex virus 2 (HSV-2) reactivations in humans are subclinical and associated with rapid expansion and containment of virus. Previous studies have shown that CD8 1 T cells persist in genital skin and mucosa at the dermal-epidermal junction (DEJ)the portal of neuronal release of reactivating virus-for prolonged time periods after herpes lesions are cleared 1, 2 . The phenotype and function of this persistent CD8 1 T-cell population remain unknown. Here, using cell-type-specific laser capture microdissection, transcriptional profiling and T-cell antigen receptor b-chain (TCRb) genotyping on sequential genital skin biopsies, we show that CD8aa 1 T cells are the dominant resident population of DEJ CD8 1 T cells that persist at the site of previous HSV-2 reactivation. CD8aa 1 T cells located at the DEJ lack chemokine-receptor expression required for lymphocyte egress and recirculation, express gene signatures of T-cell activation and antiviral activity, and produce cytolytic granules during clinical and virological quiescent time periods. Sequencing of the TCR b-chain repertoire reveals that the DEJ CD8aa 1 T cells are oligoclonal with diverse usage of TCR variable-b genes, which differ from those commonly described for mucosa-associated invariant T cells and natural killer T cells. Dominant clonotypes are shown to overlap among multiple recurrences over a period of two-and-a-half years. Episodes of rapid asymptomatic HSV-2 containment were also associated with a high CD8 effector-to-target ratio and focal enrichment of CD8aa 1 T cells. These studies indicate that DEJ CD8aa 1 T cells are tissue-resident cells that seem to have a fundamental role in immune surveillance and in initial containment of HSV-2 reactivation in human peripheral tissue. Elicitation of CD8aa 1 T cells may be a critical component for developing effective vaccines against skin and mucosal infections.
Clinical studies have shown that 50-80% of HSV reactivations are subclinical and of short duration (,6 h) [3] [4] [5] , and that CD8 1 T cells not only infiltrate selectively to the site of viral reactivation, but also persist locally at the DEJ for months after resolution of herpes lesions 1, 2 . To define the phenotype, function and diversity of these DEJ CD8 1 T cells during virological quiescence as well as early containment of reactivation, we used cell-type-specific laser capture microdissection (LCM) to identify and select individual CD8 1 T cells from the DEJ (DEJ CD8), dermis near to blood vessels (BV CD8), HSV-2-affected area, and contralateral HSV-2-unaffected genital tissue (control CD8) (Supplementary Fig. 1a , b) to examine the persistent nature, antiviral signature and TCR repertoire of these cells from sequential skin biopsies. The purity of captured CD8 cells was validated by the abundance of CD8A and the absence of CD4 gene expression ( Supplementary Fig. 1c ). Detailed immunofluorescent staining demonstrated that DEJ CD8 1 T cells expressed CD3e and TCRb, but not TCRcd ( Supplementary Fig. 2 ). These cells did not express co-receptors and markers for dendritic cells or natural killer (NK) cells or non-conventional T cells such as NKT cells and mucosa-associated invariant T (MAIT) cells ( Supplementary Fig. 3 ). Thus, the CD8 1 T cells that persist at the DEJ are CD8 1 TCRab T cells.
Because tissue-based CD8 1 T cells and memory precursors have been shown to express varied levels of CD8a and CD8b 6,7 , we measured gene expression of these co-receptors by quantitative TaqMan PCR. DEJ CD8 cells almost exclusively expressed CD8A messenger RNA. CD8B was detected in only one out of eight and three out of ten subjects biopsied at 2 and 8 weeks post-healing (w.p.h.) from the HSV-2-affected area, respectively. By contrast, BV CD8 cells from the same 8 w.p.h. biopsies expressed high levels of CD8B transcripts in nine out of ten patients ( Fig. 1a ). Cell-surface expression of CD8a and CD8b chains circumstantiated these transcriptional patterns (Fig. 1b , c). CD8a 1 b 2 cells predominated at the DEJ from the time of active lesion to 2 and 8 w.p.h., ranging from 85 to 91% of the total DEJ CD8a 1 cells, and the number of these cells remained relatively stable. By contrast, CD8a 1 b 1 cells localized mainly to the dermis during HSV-2 ulceration and rapidly *These authors contributed equally to this work. 1 diminished after completely healing, resulted in a 98% reduction in cell density during the first 2 w.p.h. at a rate (169 cells per mm 2 per week) almost ten times higher than that of CD8a 1 b 2 cells at the DEJ (17.5 cells per mm 2 per week) for the same period. When detected in either 2 or 8 w.p.h. biopsy tissue, CD8a 1 b 1 cells were mainly located near the blood vessels. These data indicate, at both the RNA and protein level, that CD8 1 T cells that selectively persist and preferentially localize at the DEJ have a CD8aa homodimer phenotype. To investigate the potential mechanism for persistence of CD8aa 1 T cells at the DEJ, we compared the transcriptional profiles of DEJ CD8 versus BV CD8 cells isolated from the same tissue biopsy obtained at 2 and 8 w.p.h. Gene expression of chemokine receptors and lymphocytetrafficking receptors was different between DEJ CD8 and BV CD8 cells. We observed a downregulation of CCR7, CCR8, CXCR4, CXCR6, CXCR7 and S1PR1 transcripts in DEJ CD8 compared to BV CD8 cells ( Fig. 2a ). Using TaqMan PCR, we found no detectable CCR7 gene expression in DEJ CD8 cells from 8 w.p.h. tissue in nine out of ten subjects; an expression pattern also observed for S1PR1, which was undetectable in eight out of ten subjects (Fig. 2b) . Comparatively, high levels of CCR7 and S1PR1 expression were detected in BV CD8 cells. It has been shown that CCR7 is required for guiding lymphocytes exiting peripheral tissue and S1PR1 functions in lymphocyte recirculation and trafficking in the blood [8] [9] [10] [11] . The absence of transcriptional activity of both of these genes in DEJ CD8 cells suggests that a potential mechanism for CD8aa 1 T-cell persistence at the DEJ is a lack of chemotactic requirements for exit.
We also compared expression profiles of genes critical for T-cell activation and antiviral and cytolytic function between captured DEJ CD8 and control CD8 cells from 8 w.p.h. biopsies 12 , a time of presumptive virological quiescence. Upregulation of genes for TCR coreceptors (CD8A and CD3G) and co-stimulation (ICOS and ITGAL (also known as LFA-1A)), G1/S cell cycle transition (CD27 and CCND3), cytolytic activity (PRF1, GZMA, GZMB, GZMK and GZMH) and cytokines/chemokines and their receptors (IFNG, TNFA, RANTES (also known as CCL5) and IL-7RA (also known as IL7R)) suggests that DEJ CD8 cells were actively engaging and eliminating infection ( Fig. 2c ). We performed quantitative PCR on a subset of these genes to delineate the expression patterns further (Fig. 2d ). Expression of RANTES and GZMA was upregulated in DEJ CD8 cells from all nine subjects. GZMB and IFNG were induced in seven and six out of nine subjects, respectively, a significantly higher proportion compared to contralateral control samples (one out of nine) (P , 0.01, Fisher's exact test). Perforin protein expression was also detected in DEJ CD8 cells at 8 w.p.h. (Fig. 2e ); no perforin granules were detected in the contralateral control CD8 cells (data not shown). The strongest perforin granule expression at the 8 w.p.h. time point was seen in DEJ cells from patients who had evidence of subclinical HSV-2 shedding ( Fig. 2e ). Co-staining of biopsy tissue showed that perforin granules were detected in DEJ CD8a 1 b 2 cells ( Fig. 2f upper panels) but not in BV CD8a 1 b 1 T cells ( Fig. 2f lower panels). The expression of cytolytic granules and mRNA patterns of T-cell activation and antiviral responses indicate that DEJ CD8aa 1 T cells are programmed and regulated to respond to virus infection.
We investigated the role of CD8aa 1 T cells in the early containment of HSV-2 reactivation during episodes of subclinical recurrence. HSV-2 DNA was detected in tissue sections in two of the ten 8 w.p.h. biopsies. 
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DNA levels were significantly lower than those during a genital lesion (,20 copies per 5 3 10 4 cells versus 10 6 copies per 5 3 10 4 cells, respectively) and the biopsies concurrently showed no histologic evidence of ulceration or epithelial cell necrosis, indicating an episode of spontaneous asymptomatic shedding controlled by the host immune system 1, 13, 14 . Immunofluorescence staining revealed a punctate distribution of HSV-2 antigen in several keratinocytes dispersed in the epidermis (Fig. 3a) . CD8 1 T cells and HSV-2-infected cells formed clusters in which two to four CD8 1 T cells were in direct contact with a virally infected cell (Fig. 3b ). This high effector-to-target ratio during asymptomatic shedding is in contrast to that which occurs during clinical episodes of recurrent genital herpes (Fig. 3c) . In situ quantum dot 655conjugated peptide-major histocompatibility complex I (Qdot655-pMHCI) multimer staining identified HSV-2-specific CD8 1 T cells present in these shedding biopsies ( Supplementary Fig. 4 ) along with increased numbers of perforin granules (Fig. 3d ), providing evidence of antigen-specific early containment of virus infection. Furthermore, high-density CD8aa 1 T cells were found in foci at the DEJ and there was increased recruitment of CD8a 1 b 1 T cells to the DEJ (Fig. 3e ). Again, we detected perforin granule expression in CD8a 1 b 2 T cells, suggesting these CD8aa 1 T cells are cytolytically active during early host antiviral control ( Supplementary Fig. 5 ). These studies suggest that CD8aa 1 T cells are important effectors in early immune containment.
In order to understand the persistence, diversity and specificity of CD8aa 1 T cells at the DEJ further, we analysed the amino acid sequence in the hypervariable complementarity-determining region 3 (CDR3) of the T-cell receptor b chain (TCRB) in DEJ CD8 cells using highthroughput sequencing assays 15 . We collected DEJ CD8 cells using LCM from six biopsies obtained during a 2.5-year time period from an individual with long-standing recurrent HSV-2 who participated in a series of trials involving sequential skin biopsies during and after HSV-2 reactivation (Fig. 4a ). The sequence pattern of DEJ CD8aa 1 T cells indicated an oligoclonal immune profile, with the top six mostabundant sequences making up 85 to 98% of the TCRB repertoire in each DEJ CD8 sample ( Fig. 4a and Supplementary Table 1 ). Twelve TCRB CDR3 sequences were common among the six tissue biopsies ( Fig. 4a and Supplementary Table 2 ): two sequences were detected in all six biopsies and one was present in five biopsies over the 2.5-year time period (Fig. 4b) . Moreover, both the abundant sequences and the 12 commonly shared sequences ( Supplementary Tables 1 and 2 ) involved diverse usage of variable-b-gene (VB) families; for example, 18 VB genes were found among the 27 unique TCRB amino acid sequences that predominated in DEJ CD8aa 1 T cells. Interestingly, evidence of constrained VB gene usage as described in CD8aa 1 MAIT cells was not seen 16, 17 ; Vb2 and Vb13 families not found in DEJ CD8 cells.
To examine the antigen specificity of DEJ CD8aa 1 T cells, we sequenced TCRB from tissue-infiltrating T cells during lesion healing, peripheral blood mononuclear cell (PBMC)-derived CD8aa 1 T cells and HSV-2-reactive CD8 1 T cells isolated directly ex vivo from PBMCs from the same individual 18 . Fifteen TCRB CDR3 sequences were shared by all three T-cell populations ( Fig. 4c and Supplementary Table 3 ), and one of these sequences, CASRLDRGTLTDTQYF, was also detected in DEJ CD8 cells from two separate biopsies 21 population that responds to HSV-2 infection in genital tissue. The sequence CASRLDRGTLTDTQYF and the two commonly shared sequences in all six DEJ CD8 samples, CASSLLAGHTGELFF and CASRKTGIPSEQYF, were abundant in the lesion-healing biopsy sample. These sequences were ranked numbers 2, 6 and 12 in frequency among 4,678 unique TCR sequences detected, further supporting the important role of DEJ CD8aa 1 T cells in response to HSV-2 antigen in tissue.
Our studies demonstrate the ability to dissect cell-type-specific immune responses in situ in humans and provide several new insights into the tissue-resident immunity in genital skin and mucosa. Accumulating evidence indicates that antigen-specific CD8 1 T cells retain longterm residence at the peripheral site of infection, exhibiting superior protection over their blood counterparts against re-infection of invading pathogens 1, [19] [20] [21] [22] [23] [24] [25] . Our human studies have shown that CD8 1 T cells persisting at the DEJ site of previous HSV-2 lesions possess a CD8aa homodimer phenotype. The persistence of CD8aa 1 T cells contrasts with the rapid depletion of CD8a 1 b 1 T cells after lesion healing. These CD8aa 1 T cells lack chemotactic signals, such as CCR7 and S1PR1, distinguishing them from circulating CD8a 1 b 1 T cells.
The detailed characterization of cell-type-specific markers and TCR VB gene diversity indicate the CD8aa 1 T cells described in this study are not innate or semi-innate T cells; rather, they are components of the adaptive immune response retained in the barrier tissue as sentinel cells. CD8aa homodimer expression has been associated with highaffinity antiviral effector T cells and proposed to preserve optimal effector cells at the portal of pathogen entry for long-lived mucosal memory 7, 26 . Whether DEJ CD8aa 1 T cells are directed at a unique class of viral antigens is unknown and is of major interest.
The unique anatomic localization of DEJ CD8aa 1 T cells contiguous to the neural gateway of reactivating virus suggested these cells might recognize and contain HSV infection. Although the functional relevance remains to be proven, the activated gene signature, oligoclonal immune profile and HSV-2-specific T-cell response at sites of previous reactivation support the notion that DEJ CD8aa 1 T cells might mediate a rapid and effective peripheral immunity to control frequent HSV antigen exposure in human skin and genital tract. The prompt CD8 antiviral response at the site of virus release during asymptomatic HSV reactivation is in sharp contrast to the delayed CD8 1 T-cell infiltration during a lesion-forming herpes recurrence, in which CD8 1 T-cell infiltration occurs 2 to 3 days after initial infection, after NKT-cell and CD4 1 T-cell arrival 27, 28 . Enhancement of the quantity and the function of tissue-resident CD8aa 1 T cells may potentially be a mechanism for improved immunotherapeutic treatment and for prevention of HSV-2 reactivation in humans. Similarly, the immunological role of these persisting T cells in other chronic infections of the skin and genital tract, such as HIV, should also be explored.
METHODS SUMMARY
All human genital skin biopsies were obtained according to a study protocol and informed consent procedures approved by the University of Washington Institutional Review Board. For a detailed description of all techniques used in this study, please see Methods.
Full Methods and any associated references are available in the online version of the paper.
METHODS
Human biopsies. The study protocol, biopsy procedure and informed consent were approved by the University of Washington Institutional Review Board. Enrolled subjects had culture-proven symptomatic genital HSV-2 infection and were all HIV-1/2 seronegative. All genital skin biopsies were collected from HSV-2-seropositive immunocompetent adults at the time of active lesion and then at 2 and 8 weeks after complete lesion healing, and from contralateral unaffected (control) genital skin 1, 2, 12 . Tissue biopsies were snap frozen in optimum cutting temperature compound within 12 h of collection and stored at 280 uC until processing. Peripheral blood was collected at the same time points. Immunofluorescence staining. Detection of T-cell markers, viral antigen and HSV-2-specific CD8 1 T cells in genital tissue was performed as described 1, 2 . Tyramide signal amplification (TSA; Invitrogen) was applied for the first antibody in dual staining, followed by incubation with CD8a-Alexa Fluor 647 (AF647). For triple staining, sequential TSA was performed by first applying antibody to perforin and then antibody to CD8b, followed by incubation with CD8a-AF647. Antibodies used in this study are listed in Supplementary Table 4 . CD8-specific LCM. Frozen tissue was sectioned into 8-mm slices and placed on a polyethylene naphthalate membrane slide (Carl Zeiss). Tissue sections were fixed in 100% ethanol, incubated with CD8a-AF647 on ice for 5 min, washed in PBS and dried with ethanol (75%, 95% and 100%) and xylene. CD8 1 cells were identified and laser microdissected using either a PALM MicroBeam instrument (Carl Zeiss) or an Arcturus Veritas microdissection system (Molecular Devices). About 100 CD8 1 cells were laser captured from each sample for transcriptional analysis, unless otherwise specified. RNA extraction, complementary DNA amplification and hybridization to Illumina bead arrays. Total RNA from LCM-captured CD8 cells from each group were extracted using Arcturus PicoPure RNA Isolation kits (Life Technologies) and quantified by a NanoDrop 1000 Spectrophotometer. One nanogram of total RNA was then used to generate and amplify cDNA through whole-transcriptome amplification using WT-Ovation Pico RNA Amplification System (NuGEN). The cDNA were biotin labelled following a protocol from NuGEN and labelled cDNA (750 ng) were then used to hybridize to Illumina HumanRef8 v3 bead arrays in the Shared Resources at Fred Hutchison Cancer Research Center. Bead array data analysis. Detailed analysis has been described previously 12 . In brief, raw data were imported to GenomeStudio (v2010.3, Illumina) for initial quality control. Normalized data were then exported to R and differentially expressed genes between DEJ CD8 and control CD8 or between DEJ CD8 and BV CD8 were selected. The differentially expressed genes were analysed further using an unsupervised hierarchical clustering method and using Spotfire DecisionSite for functional genomics (v9.1.2). Enriched functional categories and network analysis for the set of differentially expressed genes were performed using Ingenuity Pathway Analysis (IPA 8.8). The GoMiner program was used to annotate all the 18,401 genes on HumanRef8 v3 bead arrays. Microarray data accession numbers. Complete gene expression array data for DEJ CD8, control CD8 and BV CD8 can be accessed under Gene Expression Omnibus accession numbers GSE39625 and GSE44975. TaqMan quantitative PCR. TaqMan PCR assays were performed using primer/ probe sets obtained from Applied Biosystems ( Supplementary Table 5 ). Relative expression to ACTB is shown for each gene. HSV-2 DNA detection in tissue was described previously 1, 29 . DNA extraction and amplification. Genomic DNA from laser capture microdissected CD8 1 T cells was extracted using Arcturus PicoPure DNA Extraction kits (Life Technologies). Recovered DNA was whole-genome amplified through multiple displacement amplification using REPLI-g Mini kit (Qiagen). TCRb sequencing. TCR b-chain sequencing was performed at Adaptive Biotechnologies using the ImmunoSEQ platform 15 . All TCRb chains were PCR amplified from 400 ng of DNA from each sample. The library was sequenced using Illumina HiSeq and the resulting reads were processed and uploaded onto the ImmunoSEQ Analyzer secure relational database. Purification of HSV reactive CD8 1 T cells from PBMC ex vivo. We obtained bulk HSV-2 reactive CD8 T cells as described previously 18 and adapted the method for HSV-2. HSV-2-infected HeLa cell debris was added to cultured PBMC-derived dendritic cells, which were then incubated with negatively selected CD8 T cells from the same subject and stained with 7-aminoactinomycin D for viability assessment and with anti-CD8a, anti-CD3 and anti-CD137 conjugated to fluorochromes. The cells were sorted on a FACSAria III instrument and live, CD3 1 , CD8a 1 and CD137 bright cells were selected. Approximately 5,000 directly sorted cells were submitted for TCRb sequencing. Purification, sorting and deep sequencing of CD8aa 1 T cells from PBMC. CD8aa T cells were purified from PBMC and labelled with antibodies of CD8a Pacific Blue, CD8b APC, CD3 APC-Cy7, TCRab 1 Alexa 488 and CD4 phycoerythrin-Cy7. The cells were sorted using BD FACSAria. CD8aa T cells, described as CD3 1 TCRab 1 CD4 2 CD8a 1 CD8b 2 , were collected and expanded using a rapid expansion protocol 30 in the presence of 50 IU ml 21 of recombinant human IL-2 and 1 ng ml 21 of recombinant human IL-7. A total of 890,000 CD8a 1 b 2 CD4 2 T cells (98% pure) were collected and submitted to Adaptive Biotechnologies for TCRb deep sequencing.
